ArticleFrontiers in oncology2020
Problems and Promises of Introducing the Magnetic Resonance Imaging Linear Accelerator Into Routine Care: The Case of Prostate Cancer.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- MRI-enhanced online adaptive radiotherapy by virtual integration of a standalone MRI simulator and CBCT-based treatment delivery.Radiation oncology (London, England) · 2026Article
- Multiscale Segmentation-Guided Diffusion Model for CBCT-to-CT Synthesis.Life (Basel, Switzerland) · 2025Article
- Treatment time and learning curve analysis of 1.5 T MR-Linac workflows led by radiation oncologists or therapists.Clinical and translational radiation oncology · 2025Article
- The NASSS (Non-Adoption, Abandonment, Scale-Up, Spread and Sustainability) framework use over time: A scoping review.PLOS digital health · 2025Article
- Institutionalisation of convergent medical innovation: an empirical study of the MRI-guided linear accelerator in the Netherlands and the United States.Innovation (North Sydney, N.S.W.) · 2025Article
- Safety and Tolerability of Online Adaptive High-Field Magnetic Resonance-Guided Radiotherapy.JAMA network open · 2024Article
- Article
- Clinical and Dosimetric Impact of 2D kV Motion Monitoring and Intervention in Liver Stereotactic Body Radiation Therapy.Advances in radiation oncology · 2024Article
- Realizing the value of complex medical technology: Demonstrating cost-effectiveness is not enough.Clinical and translational radiation oncology · 2023Article
- Old dogs, new tricks: MR-Linac training and credentialing of radiation oncologists, radiation therapists and medical physicists.Journal of medical radiation sciences · 2023Article
- Delineation uncertainties of tumour volumes on MRI of head and neck cancer patients.Clinical and translational radiation oncology · 2022Article
- Clinical Implementational and Site-Specific Workflows for a 1.5T MR-Linac.Journal of clinical medicine · 2022Article
- Case Report: MR-Guided Adaptive Radiotherapy, Some Room to Maneuver.Frontiers in oncology · 2022Article
- The impact of image acquisition time on registration, delineation and image quality for magnetic resonance guided radiotherapy of prostate cancer patients.Physics and imaging in radiation oncology · 2021Article
- MR-Guided Hypofractionated Radiotherapy: Current Emerging Data and Promising Perspectives for Localized Prostate Cancer.Cancers · 2021Review
- Article
- Implementation of Magnetic Resonance Imaging-Guided Radiation Therapy in Routine Care: Opportunities and Challenges in the United States.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The new radiotherapy high field, 1.5 Tesla MRI-guided linear accelerator (MR-Linac) is being clinically introduced. Sensing and evaluating opportunities and barriers at an early stage will facilitate its eventual scale-up. This study investigates the opportunities and barriers to the implementation of MR-Linac into prostate cancer care based on 43 semi-structured interviews with Dutch oncology care professionals, hospital and division directors, patients, payers and industry. The analysis was guided by the Non-adoption, Abandonment, Scale-up, Spread, and Sustainability framework of new medical technologies and services. Opportunities included: the acquirement of (1) advanced MRI-guided radiotherapy technology with (2) the potential for improved patient outcomes and (3) economic benefits, as well as (4) professional development and (5) a higher hospital quality profile. Barriers included: (1) technical complexities, (2) substantial staffing and structural investments, (3) the current lack of empirical evidence of clinical benefits, (4) professional silos, and (5) the presence of patient referral patterns. While our study confirms the expected technical and clinical prospects from the literature, it also reveals economic, organizational, and socio-political challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.